DRRX: DURECT Corp Company Short-Term Debt

Symbol and logo of brand DURECT Corp (DRRX)

DURECT Corporation (DRRX) maintains a stable level of short-term debt, supported by the development of exclusive methods for protecting organs from pathologies, with 0.00 serving as the current value of this metric. This trend reflects the outsourcing of all research to external contractors and the existence of significant patent barriers in epigenetics, which block new entrants from entering the liver therapy market.

DRRX (durect.com) Company Short-Term Debts history from 07/04/2022 to 09/27/2025

DURECT Corp - analytical breakdowns and key metrics (DRRX)

- current quotes and average value forecast:
Price Chart DURECT Corp.|DRRX - Fair Value Consensus
- market capitalization information:
Market Value DURECT Corporation|DRRX - Real Price to Acquire Entire Company
- shareholders' equity book value data:
Book Value per Share DURECT|DRRX - Book Capitalization|Market Cap to Net Assets Ratio durect.com|DRRX - Aggregate Asset Value
- debt and liquidity data:
Debt to Equity DURECT Corporation|DRRX - Long-Term Debt to Equity|Short-Term Debt to Capital DURECT Corp.|DRRX - Company Total Debt Obligations|Debt to Book Value DURECT Corporation|DRRX - Company Long-Term Debt|Company Short-Term Debts DURECT|Quick Liquidity durect.com
- net income and valuation multiples indicators:
DRRX - Final Profit
Fundamental company analysis:durect.com - DRRX
Mass-produced product of DURECT Corp

When screening business quality, an investor assesses liquidity via the total amount of liabilities maturing within one year, which determines the enterprise's financial stability. For DURECT Corporation (DRRX), which lacks revenue due to an absence of commercial sales and a dependence on testing phases, the short-term debt trajectory becomes a critical indicator of the company's ability to fund research without emergency equity dilution.

Competitor analysis for DURECT Corporation

ARWR - Company Short-Term Debt|Company Short-Term Loans and Borrowings MIRM (Mirum Pharmaceuticals, Inc.)|Dynavax (DVAX) - Company Short-Term Debt|Company Current Liabilities Tekmira Pharmaceuticals|IVA (Inventiva S.A.) - Company Short-Term Debts|Company Short-Term Debts gyretx.com|Company Current Liabilities ASMB (Assembly Biosciences, Inc.)|GALT (galectintherapeutics.com) - Company Short-Term Loans and Borrowings|Company Short-Term Debt GENFIT GNFT|Aligos Therapeutics Inc. - Company Short-Term Debt|BioVie Pharma - Company Short-Term Debts|Short-Term Debt Volume Galmed Pharmaceuticals GLMD|NDRA (ENDRA Life Sciences Inc.) - Company Current Liabilities|HEPA (Hepion Pharmaceuticals, Inc.) - Company Short-Term Debt